Abstract
The IV infusions of both prostaglandin E1 (PGE1) and pentoxifylline showed good efficacy in prolonging the claudication distance and maximum walking range of patients with intermittent claudication, and the Doppler pressures were used as parameters of efficacy. IV PGE1 was significantly superior after 4 weeks' therapy as to both claudication distance and maximum walking range. The ankle pressure indices were significantly elevated in both groups at the end of therapy. The therapeutic effect proved to persist in both groups after a 12 month follow-up, with adverse reactions occurring in two patients treated with PGE1 and in six patients treated with pentoxifylline. The study supports the view that the intravenous infusion of PGE1 is an efficacious and well-tolerated therapy for intermittent claudication.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
